We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+19.55%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$19.7M
AUM Growth
+$2.18M
Cap. Flow
+$244K
Cap. Flow %
1.23%
Top 10 Hldgs %
99.71%
Holding
12
New
1
Increased
5
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
LXEO icon
Lexeo Therapeutics
LXEO
+$109K
2
KYTX icon
Kyverna Therapeutics
KYTX
+$109K
3
CNTX icon
Context Therapeutics
CNTX
+$31.7K
4
DFTX
Definium Therapeutics
DFTX
+$11.5K
5
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$6.8K

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$27.3K

Sector Composition

Rank Sector Weight
1 Healthcare 92.73%
2 Financials 2.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XERS icon
1
Xeris Biopharma Holdings
XERS
$1.5B
$11.5M 58.31%
5,113,348
– –
RZLT icon
2
Rezolute
RZLT
$421M
$5.67M 28.74%
1,318,967
– –
SPY icon
3
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$1.02M 5.15%
1,869
+13
+0.7% +$6.8K
BRK.B icon
4
Berkshire Hathaway Class B
BRK.B
$1.06T
$417K 2.11%
1,025
+6
+0.6% +$2.45K
LXEO icon
5
Lexeo Therapeutics
LXEO
$358M
$286K 1.45%
17,851
+7,532
+73% +$109K
DFTX
6
Definium Therapeutics
DFTX
$5.85B
$219K 1.11%
30,383
+1,318
+5% +$11.5K
ABVX
7
Abivax
ABVX
$12B
$184K 0.93%
13,900
-1,908
-12% -$27.3K
KYTX icon
8
Kyverna Therapeutics
KYTX
$452M
$172K 0.87%
22,981
+7,135
+45% +$109K
MTEM
9
DELISTED
Molecular Templates, Inc.
MTEM
$157K 0.8%
136,866
– –
CMPX icon
10
Compass Therapeutics
CMPX
$378M
$43.5K 0.22%
43,465
– –
CNTX icon
11
Context Therapeutics
CNTX
$56.5M
$36.9K 0.19%
+18,403
New +$31.7K
ACET icon
12
Adicet Bio
ACET
$76.8M
$21.2K 0.11%
1,093
– –

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q2 2024 Portfolio in Review

As of Q2 2024, Caxton Corporation held 12 positions worth $19.7M, up 12% from $17.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation's Q2 2024 filing shows 1 new, 5 increased and 1 reduced positions. Its largest new stake was Context Therapeutics: 18,403 shares worth $36.9K. The largest sale was Abivax, an estimated $27.3K.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials.

  • Caxton Corporation's largest Q2 2024 buy was Context Therapeutics: 18,403 shares worth $36.9K.
  • Caxton Corporation added most to Lexeo Therapeutics in Q2 2024, an estimated $109K increase.
  • Caxton Corporation's biggest Q2 2024 reduction was Abivax, cutting an estimated $27.3K.
  • Caxton Corporation's ten largest holdings make up 100% of its $19.7M portfolio in Q2 2024.
  • Caxton Corporation opened 1 new position and closed 0 in Q2 2024.
  • Caxton Corporation's portfolio value rose 12% quarter-over-quarter to $19.7M.

Based on Caxton Corporation's 13F filing for Q2 2024, filed 14 Aug 2024.